PREMAS Biotech launched its suite of recombinant Human Cytochrome P450 Isozymes expressed in Saccharomyces cerevisiae. These Microsomes contain human CYP450 isozyme and human NADPH oxido reductase hence offering significantly higher specific activity and performance.
PREMAS will be launching following CYP450 isozymes in the first phase.
- CYP3A4 along with Human NADPH oxidoreductase and Cytochrome b5,
- CYP2D6 along with Human NADPH oxidoreductase,
- CYP2E1 along with Human NADPH oxidoreductase,
- CYP1A2 along with Human NADPH oxidoreductase,
- CYP2C9 along with Human NADPH oxidoreductase and Cytochrome b5,
- CYP2C19 along with Human NADPH oxidoreductase,
These Microsomes will be available in user friendly pack sizes and their commercial availability will be from mid April 2009.
Visit PREMAS Biotech at ToxExpo 2009 at Booth #1780.
www.premasbiotech.com
